<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Gastroenterol Hepatol Bed Bench</journal-id><journal-id journal-id-type="iso-abbrev">Gastroenterol Hepatol Bed Bench</journal-id><journal-id journal-id-type="publisher-id">GHFBB</journal-id><journal-title-group><journal-title>Gastroenterology and Hepatology From Bed to Bench</journal-title></journal-title-group><issn pub-type="ppub">2008-2258</issn><issn pub-type="epub">2008-4234</issn><publisher><publisher-name>Research Institute for Gastroenterology and Liver Diseases</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24834261</article-id><article-id pub-id-type="pmc">4017509</article-id><article-id pub-id-type="publisher-id">GHFBB-6-141</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Evaluation of the benefit of addition of clidinium C to a <italic>Helicobacter pylori</italic> eradication regimen</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chorami</surname><given-names>Maryam</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zojaji</surname><given-names>Homayoun</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Naderi</surname><given-names>Nosratollah</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Moghimi-Dehkordi</surname><given-names>Bijan</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Mirsattari</surname><given-names>Dariush</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Shalmani</surname><given-names>Hamid Mohaghegh</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran</aff><aff id="AF0002"><label>2</label>Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran</aff><author-notes><corresp id="cor1"><bold>Reprint or Correspondence:</bold> Homayoun Zojaji, MD. Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. <bold>E-mail:</bold><email xlink:href="zojaji@yahoo.com">zojaji@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Summer</season><year>2013</year></pub-date><volume>6</volume><issue>3</issue><fpage>141</fpage><lpage>145</lpage><history><date date-type="received"><day>15</day><month>1</month><year>2013</year></date><date date-type="accepted"><day>18</day><month>5</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 Research Institute for Gastroenterology and Liver Diseases</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.</license-p></license></permissions><abstract><sec id="st1"><title>Aim</title><p>This study aimed to evaluate the success of <italic>H.pylori</italic> eradication therapy in patients with dyspepsia by therapeutics regimes with and without clidinium C.</p></sec><sec id="st2"><title>Background</title><p>Helicobacter pylori infections are reported in all parts of the world. Appropriate antibiotic therapy can treat infection. The ideal treatment regimen has not been specified.</p></sec><sec id="st3"><title>Patients and methods</title><p>In a randomized, double blind clinical trials study, 250 patients with dyspepsia were enrolled. All patients were treated by Omeprazole, Metronidazole, Amoxicillin and Bismuth (OMAB) for two weeks. One tablet clidinium C before each meal was added to this regimen in the intervention group (A). Urea Breath Test (UBT) was carried out after 8-12 weeks after treatment for evaluation of H.pylori eradication.</p></sec><sec id="st4"><title>Results</title><p>132 patients in the intervention group (A) and 118 patients in the control group (B) were enrolled to the study. The rate of eradication in group A was significantly higher than group B (62.1% vs. 50%, p=0.04).</p></sec><sec id="st5"><title>Conclusion</title><p>The results supported the effect of clidinium C for increasing of helicobacter pylori eradication, but further studies need to be performed.</p></sec></abstract><kwd-group><kwd><italic>Helicobacter pylori</italic></kwd><kwd>Eradication rate</kwd><kwd>Quadruple therapy</kwd><kwd>Clidinium C</kwd></kwd-group></article-meta><notes><p><bold>(</bold>Please cite as: <bold>Chorami M, Zojaji H, Naderi N, Moghimi-Dehkordi B, Mirsattari D, Mohaghegh Shalmani H. Evaluation of the benefit of addition of clidinium C to a <italic>Helicobacter pylori</italic> eradication regimen. Gastroenterol Hepatol Bed Bench 2013;6(3):141-145).</bold></p></notes></front><body><sec sec-type="intro" id="S0001"><title>Introduction</title><p>Although there is some evidence on declining the prevalence of <italic>Helicobacter pylori</italic> (<italic>H.pylori</italic>) in developed countries, the infection remains common throughout the world (<xref rid="CIT0001" ref-type="bibr">1</xref>).</p><p>
<italic>H.pylori</italic> is related with common gastrointestinal diseases such as non-ulcer dyspepsia, peptic ulcer and gastric malignancies (<xref rid="CIT0002" ref-type="bibr">2</xref>, <xref rid="CIT0003" ref-type="bibr">3</xref>). <italic>H. pylori</italic> infection persists throughout life. Antibiotic therapy is needed for eradication (<xref rid="CIT0004" ref-type="bibr">4</xref>, <xref rid="CIT0005" ref-type="bibr">5</xref>).</p><p>Due to the nature of <italic>H.pylori</italic> colonization and resistance, current antibiotic therapy is not ideal. In recent years, different combinations of antibiotics combined with a proton pump inhibitor (PPI) have been standard treatment regimens for <italic>H. Pylori</italic> eradication therapy. In approximately 10-20% of patients, <italic>H. pylori</italic> eradication is not successful and the bacterial infection persists (<xref rid="CIT0006" ref-type="bibr">6</xref>). Using standard triple therapy that includes a PPI along with clarithromycin and amoxicillin and/or metronidazole (<xref rid="CIT0007" ref-type="bibr">7</xref>, <xref rid="CIT0008" ref-type="bibr">8</xref>), treatment rates started from more than 90% and then reduced to 70-80% (<xref rid="CIT0009" ref-type="bibr">9</xref>) and in a recent study the eradication rate of triple regimen was about 55% (<xref rid="CIT0010" ref-type="bibr">10</xref>).</p><p>If <italic>H.pylori</italic> eradication with the triple therapy fails, a quadruple therapy using bismuth, metronidazole, and, tetracycline, together with a PPI is advised (<xref rid="CIT0011" ref-type="bibr">11</xref>). Resistance to antibiotics, especially clarithromycin, is an important reason for the loss of eradication therapy (<xref rid="CIT0012" ref-type="bibr">12</xref>, <xref rid="CIT0013" ref-type="bibr">13</xref>).</p><p>Over the past few years, some studies have investigated the effect of adding a further therapy, such as a supplement of vitamin C, vitamin E, and cobalamin to the therapeutic regimen. Some of these studies have shown that these supplements can improve the efficacy of <italic>H.pylori</italic> eradication regimens, but others have not reported any beneficial effects (<xref rid="CIT0014" ref-type="bibr">14</xref>&#x02013;<xref rid="CIT0019" ref-type="bibr">19</xref>).</p><p>Duration of penetration is one of the most important factors that can increase the effect of antibiotic efficacy in the treatment of <italic>H.pylori</italic>. A pharmaceutical agent that can increase the duration of antibiotic penetrance may be useful for the successful eradication of infection (<xref rid="CIT0020" ref-type="bibr">20</xref>). In this study we investigated the effect of adjutant therapy with clidinium C on the eradication of <italic>H. pylori</italic>. clidinium, in combination with other drugs, has been shown to have an antispasmodic and an anxiolytic effect. It also helps in the treatment of peptic ulcer disease and irritable bowel syndrome (<xref rid="CIT0021" ref-type="bibr">21</xref>). We think that reducing gastric acidity and motility due to consumption of clidinium C can increase the efficacy and penetration of amoxicillin to the gastric superficial mucosa and so improve the efficacy of quadruple therapy for eradication of infection.</p><p>To our knowledge, no study has been conducted on this issue. Thus, we aimed to investigate the effect of adding one tablet clidinium C to the standard quadruple therapy for the eradication of <italic>H.pylori</italic>.</p></sec><sec sec-type="methods" id="S0002"><title>Patients and Methods</title><p>This study was designed as a double blind randomized clinical trial on 250 consecutive patients who had referred to Taleghani Hospital in Tehran with an indication for endoscopy of dyspeptic or other gastrointestinal symptoms. Patients with angle closure glaucoma, toxic megacolon, ulcerative colitis, intestinal obstruction, pyloric and duodenal stenosis, obstructive uropathy, benign prostatic hyperplasia (BPH) and intestinal atony were excluded from the study. The study protocol was approved by the Ethics Committee of Shahid Beheshti University of Medical Sciences and written informed consent was obtained from all participants before enrolment. A specialist physician who was blinded about the study groups performed endoscopy for all patients and biopsy was obtained. All patients with a positive pathology result were randomly assigned into two groups. Both groups (A and B) were given the quadruple regimen for eradication of <italic>H.pylori</italic>, consisting of omeprazole 20mg b.i.d, metronidazole 500mg b.i.d., amoxicillin 500 mg bid.and bismuth 240mg b.i.d. (OMAB) for 2 weeks. In the intervention group, (group A) one clidinium C (Sobhan Darou, Rasht, Iran.) tablet q.i.d for 2 weeks was added to the <italic>H.pylori</italic> eradication regimen. Patient's compliance was evaluated with regular follow-ups.</p><p>The measurement of outcome was based on urea breath test (UBT) and all patients underwent UBT 8 to 12 weeks (regarding to gastric of duodenal involvement) after the end of <italic>H.pylori</italic> treatment. The negative results of UBT test were considered as successful treatment.</p><p>For statistical analysis, Chi-square test was used to compare the eradication rates between group A and B. P &#x0003c; 0.05 was considered statistically significant.</p></sec><sec sec-type="results" id="S0003"><title>Results</title><p>266 patients including 135 patients [54 male (40%) and 81 female (60%)] in group A (OMAB plus clidinium C), and 131 patients [56 male (43%) and 75 female (57%)] in group B (OMAB) underwent endoscopy. The 2 groups were similar with respect to age (48.72 &#x000b1; 56.30 years vs 40.11 &#x000b1; 14.13 years; p=0.091). Three patients in group A did not complete the treatment, and were therefore, excluded from further analysis. Thirteen patients in group B were excluded from the study for reasons, such as gastrointestinal bleeding (two patients), or failure to complete course of treatment (eleven patients). A total of 132 patients in group A and 118 patients in group B were entered to the data analysis.</p><p>
<xref ref-type="table" rid="T0001">Table 1</xref> shows the endoscopic findings of the patients at the beginning of the study. Gastroduodenitis was the most observed endoscopic finding in both groups. No significant differences were seen between group A and B regarding to endoscopic findings (p=0.218).
</p><table-wrap id="T0001" position="float"><label>Table 1</label><caption><p>Endoscopic findings in patients under study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Treatments groups</th><th align="center" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">A</td><td align="center" rowspan="1" colspan="1">B</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Endoscopic findings</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Gastroduodenitis</td><td align="center" rowspan="1" colspan="1">88(66.7%)</td><td align="center" rowspan="1" colspan="1">71(60.2%)</td><td align="center" rowspan="1" colspan="1">159(63.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Gastric ulcer</td><td align="center" rowspan="1" colspan="1">5(3.8%)</td><td align="center" rowspan="1" colspan="1">4(3.4%)</td><td align="center" rowspan="1" colspan="1">9(3.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Duodenal ulcer</td><td align="center" rowspan="1" colspan="1">1(0.8%)</td><td align="center" rowspan="1" colspan="1">5(4.2%)</td><td align="center" rowspan="1" colspan="1">6(2.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Gastroduodenal ulcer</td><td align="center" rowspan="1" colspan="1">3(2.3%)</td><td align="center" rowspan="1" colspan="1">2(1.7%)</td><td align="center" rowspan="1" colspan="1">5(2.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Gastroduodenitis and gastric ulcer</td><td align="center" rowspan="1" colspan="1">15(11.4%)</td><td align="center" rowspan="1" colspan="1">13(11.0%)</td><td align="center" rowspan="1" colspan="1">28(11.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Gastroduodenitis and duodenal ulcer</td><td align="center" rowspan="1" colspan="1">7(5.3%)</td><td align="center" rowspan="1" colspan="1">15(12.7%)</td><td align="center" rowspan="1" colspan="1">22(8.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Unknown</td><td align="center" rowspan="1" colspan="1">13(9.8%)</td><td align="center" rowspan="1" colspan="1">8(6.8%)</td><td align="center" rowspan="1" colspan="1">21(8.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">132(100%)</td><td align="center" rowspan="1" colspan="1">118(100%)</td><td align="center" rowspan="1" colspan="1">250(100%)</td></tr></tbody></table></table-wrap><p>As shown in <xref ref-type="table" rid="T0002">Table 2</xref>, group A has shown higher eradication rates compared to group B (62.1% vs. 50%, p=0.04) and adding clidinium C could increase the efficacy of the quadruple regimen for eradication of <italic>H.pylori</italic>.
</p><table-wrap id="T0002" position="float"><label>Table 2</label><caption><p>Eradication rates (UBT negative test) in patients under study on the basis of type of treatments</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1">Treatment</th><th align="center" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"/><td align="center" colspan="2" rowspan="1">
<bold>A</bold>
</td><td align="center" colspan="2" rowspan="1">
<bold>B</bold>
</td><td align="center" rowspan="1" colspan="1">0.04</td></tr><tr><th colspan="6" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>UBT results</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>N</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>%</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>n</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>%</bold>
</td><td align="center" rowspan="1" colspan="1"/></tr><tr><th colspan="5" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">Positive</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">43.2</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">62.1</td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Borderline</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">9.8</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">6.8</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></sec><sec sec-type="discussion" id="S0004"><title>Discussion</title><p>Since 1980, which <italic>H.pylori</italic> has been explored, several eradication regimens have been proposed for the treatment of this infection. All treatment regimens were based on antibiotic components and in recent years, many reports have been published on the antibiotic resistance from all parts of the world (<xref rid="CIT0022" ref-type="bibr">22</xref>&#x02013;<xref rid="CIT0028" ref-type="bibr">28</xref>). Widespread use of antibiotics, acquired resistance, poor compliance, and insufficient antibiotic penetration into the site of infection are the most important factors causing this problem. Thus, some researchers have tended to propose new regimens to improve the eradication rates. Addition of probiotics, vitamins, cobalamin and so other components are some of these efforts. In this double blind clinical trial study, we assessed the influence of adding clidinium C to the quadruple regimen for eradication of H.pylori infection. Our results shows that group A (OMAB plus clidinium C) have had a significant higher response rate to treatment in comparison to group B (62.1% vs.50%). Clidinium C with reducing the acidity and motility of the stomach could increase the duration of antibiotic penetrance and therefore, lead to better responses. Lozniewski et al. (<xref rid="CIT0020" ref-type="bibr">20</xref>) suggests that that the penetration of amoxicillin into the superficial gastric mucosa may be substantially increased in the case of H. pylori infection.</p><p>Other investigators have studied the efficacy of addition of vitamins, such as C and E to the triple or quadruple therapy for treatment of H.pylori infection. Chuang et al. (<xref rid="CIT0029" ref-type="bibr">29</xref>) and Li et al.(<xref rid="CIT0019" ref-type="bibr">19</xref>) reported that adding vitamin C and E to triple therapy could not improve the H. pylori eradication rates. Kaboli et al. (<xref rid="CIT0018" ref-type="bibr">18</xref>) obtained the same results on vitamin C supplement.</p><p>But, Zojaji et al. (<xref rid="CIT0017" ref-type="bibr">17</xref>) have found that addition of vitamin C to <italic>H.pylori</italic> treatment regimen of amoxicillin, metronidazole and bismuth can significantly increases <italic>H.pylori</italic> eradication rate.</p><p>Although many efforts have been spent to improving the efficacy of H.pylori eradication regimens, there is a substantial need for novel therapeutic strategies. Our study is one of these efforts that have shown addition of clidinium C to the standard quadruple therapy may increase the chance of H.pylori eradication. However, we recommend further studies to confirm our results.</p></sec></body><back><ack><title>Acknowledgements</title><p>This study was founded by the Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. This study resulted from Dr. Maryam Chorami thesis.</p></ack><ref-list><title>References</title><ref id="CIT0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonnenberg</surname><given-names>A</given-names></name><name><surname>Lash</surname><given-names>RH</given-names></name><name><surname>Genta</surname><given-names>RM</given-names></name></person-group><article-title>A national study of <italic>Helicobactor pylori</italic> infection in gastric biopsy specimens</article-title><source>Gastroenterology</source><year>2010</year><volume>139</volume><fpage>1894</fpage><lpage>901</lpage><pub-id pub-id-type="pmid">20727889</pub-id></element-citation></ref><ref id="CIT0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zullo</surname><given-names>A</given-names></name><name><surname>Hassan</surname><given-names>C</given-names></name><name><surname>Cristofari</surname><given-names>F</given-names></name><name><surname>Andriani</surname><given-names>A</given-names></name><name><surname>De Francesco</surname><given-names>V</given-names></name><name><surname>Ierardi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Effects of <italic>Helicobacter pylori</italic> eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma</article-title><source>Clin Gastroenterol Hepatol</source><year>2010</year><volume>8</volume><fpage>105</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">19631287</pub-id></element-citation></ref><ref id="CIT0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alakkari</surname><given-names>A</given-names></name><name><surname>Zullo</surname><given-names>A</given-names></name><name><surname>O'Connor</surname><given-names>HJ</given-names></name></person-group><article-title>
<italic>Helicobacter pylori</italic> and nonmalignant diseases</article-title><source>Helicobacter</source><year>2010</year><volume>16</volume><fpage>S33</fpage><lpage>37</lpage></element-citation></ref><ref id="CIT0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uygun</surname><given-names>A</given-names></name><name><surname>Kadayifci</surname><given-names>A</given-names></name><name><surname>Yesilova</surname><given-names>Z</given-names></name><name><surname>Safali</surname><given-names>M</given-names></name><name><surname>Ilgan</surname><given-names>S</given-names></name><name><surname>Karaeren</surname><given-names>N</given-names></name></person-group><article-title>Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia</article-title><source>Clin Ther</source><year>2008</year><volume>30</volume><fpage>528</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">18405790</pub-id></element-citation></ref><ref id="CIT0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dehghani</surname><given-names>SM</given-names></name><name><surname>Erjaee</surname><given-names>A</given-names></name><name><surname>Imanieh</surname><given-names>MH</given-names></name><name><surname>Haghighat</surname><given-names>M</given-names></name></person-group><article-title>Efficacy of the standard quadruple therapy versus triple therapies containing proton pump inhibitor plus amoxicillin and clarithromycin or amoxicillin-clavulanic acid and metronidazole for <italic>Helicobacter pylori</italic> eradication in children</article-title><source>Dig Dis Sci</source><year>2009</year><volume>54</volume><fpage>1720</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">19005755</pub-id></element-citation></ref><ref id="CIT0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romano</surname><given-names>M</given-names></name><name><surname>Cuomo</surname><given-names>A</given-names></name></person-group><article-title>Eradication of <italic>Helicobacter pylori</italic>: a clinical update</article-title><source>Med Gen Med</source><year>2004</year><volume>6</volume><fpage>19</fpage></element-citation></ref><ref id="CIT0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caselli</surname><given-names>M</given-names></name><name><surname>Zullo</surname><given-names>A</given-names></name><name><surname>Maconi</surname><given-names>G</given-names></name><name><surname>Parente</surname><given-names>F</given-names></name><name><surname>Alvisi</surname><given-names>V</given-names></name><name><surname>Casetti</surname><given-names>T</given-names></name><etal/></person-group><article-title>&#x0201c;Cervia II Working Group Report 2006&#x0201d;: guidelines on diagnosis and treatment of <italic>Helicobacter pylori</italic> infection in Italy</article-title><source>Dig Liver Dis</source><year>2007</year><volume>39</volume><fpage>782</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">17606419</pub-id></element-citation></ref><ref id="CIT0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chey</surname><given-names>WD</given-names></name><name><surname>Wong</surname><given-names>BC</given-names></name></person-group><article-title>American College of Gastroenterology guideline on the management of <italic>Helicobacter pylori</italic> infection</article-title><source>Am J Gastroenterol</source><year>2007</year><volume>102</volume><fpage>1808</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">17608775</pub-id></element-citation></ref><ref id="CIT0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paoluzi</surname><given-names>OA</given-names></name><name><surname>Visconti</surname><given-names>E</given-names></name><name><surname>Andrei</surname><given-names>F</given-names></name><name><surname>Tosti</surname><given-names>C</given-names></name><name><surname>Lionetti</surname><given-names>R</given-names></name><name><surname>Grasso</surname><given-names>E</given-names></name><etal/></person-group><article-title>Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating <italic>Helicobacter pylori</italic> infection: a randomized controlled study on efficacy and tolerability</article-title><source>J Clin Gastroenterol</source><year>2010</year><volume>44</volume><fpage>261</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">20195162</pub-id></element-citation></ref><ref id="CIT0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfertheiner</surname><given-names>P</given-names></name><name><surname>Bazzoli</surname><given-names>F</given-names></name><name><surname>Delchier</surname><given-names>JC</given-names></name><name><surname>Celinski</surname><given-names>K</given-names></name><name><surname>Giguere</surname><given-names>M</given-names></name><name><surname>Riviere</surname><given-names>M</given-names></name><etal/></person-group><article-title>Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial</article-title><source>Lancet</source><year>2011</year><volume>377</volume><fpage>905</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">21345487</pub-id></element-citation></ref><ref id="CIT0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirbagheri</surname><given-names>SA</given-names></name><name><surname>Hasibi</surname><given-names>M</given-names></name><name><surname>Abouzari</surname><given-names>M</given-names></name><name><surname>Rashidi</surname><given-names>A</given-names></name></person-group><article-title>Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial</article-title><source>World J Gastroenterol</source><year>2006</year><volume>12</volume><fpage>4888</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">16937475</pub-id></element-citation></ref><ref id="CIT0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selgrad</surname><given-names>M</given-names></name><name><surname>Malfertheiner</surname><given-names>P</given-names></name></person-group><article-title>Treatment of <italic>Helicobacter pylori</italic>
</article-title><source>Curr Opin Gastroenterol</source><year>2011</year><volume>27</volume><fpage>565</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">21946029</pub-id></element-citation></ref><ref id="CIT0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vakil</surname><given-names>N</given-names></name></person-group><article-title>
<italic>H. pylori</italic> treatment: new wine in old bottles?</article-title><source>Am J Gastroenterol</source><year>2009</year><volume>104</volume><fpage>26</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">19098845</pub-id></element-citation></ref><ref id="CIT0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>J</given-names></name><name><surname>Sanal</surname><given-names>MG</given-names></name><name><surname>Gopal</surname><given-names>GJ</given-names></name></person-group><article-title>Vitamin-C as anti-<italic>Helicobacter pylori</italic> agent: More prophylactic than curative- Critical review</article-title><source>Indian J Pharmacol</source><year>2011</year><volume>43</volume><fpage>624</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">22144762</pub-id></element-citation></ref><ref id="CIT0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chuang</surname><given-names>CH</given-names></name><name><surname>Sheu</surname><given-names>BS</given-names></name><name><surname>Kao</surname><given-names>AW</given-names></name><name><surname>Cheng</surname><given-names>HC</given-names></name><name><surname>Huang</surname><given-names>AH</given-names></name><name><surname>Yang</surname><given-names>HB</given-names></name><etal/></person-group><article-title>Adjuvant effect of vitamin C on omeprazole-amoxicillin-clarithromycin triple therapy for <italic>Helicobacter pylori</italic> eradication</article-title><source>Hepatogastroenterology</source><year>2007</year><volume>54</volume><fpage>320</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">17419283</pub-id></element-citation></ref><ref id="CIT0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahner</surname><given-names>E</given-names></name><name><surname>Persechino</surname><given-names>S</given-names></name><name><surname>Annibale</surname><given-names>B</given-names></name></person-group><article-title>Micronutrients (other than iron) and <italic>Helicobacter pylori</italic> infection: a systematic review</article-title><source>Helicobacter</source><year>2012</year><volume>17</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">22221610</pub-id></element-citation></ref><ref id="CIT0017"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zojaji</surname><given-names>H</given-names></name><name><surname>Talaie</surname><given-names>R</given-names></name><name><surname>Mirsattari</surname><given-names>D</given-names></name><name><surname>Haghazali</surname><given-names>M</given-names></name><name><surname>Molaei</surname><given-names>M</given-names></name><name><surname>Mohsenian</surname><given-names>N</given-names></name><etal/></person-group><article-title>The efficacy of <italic>Helicobacter pylori</italic> eradication regimen with and without vitamin C supplementation</article-title><source>Dig Liver Dis</source><year>2009</year><volume>41</volume><fpage>644</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">19493713</pub-id></element-citation></ref><ref id="CIT0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaboli</surname><given-names>SA</given-names></name><name><surname>Zojaji</surname><given-names>H</given-names></name><name><surname>Mirsattari</surname><given-names>D</given-names></name><name><surname>Talaie</surname><given-names>R</given-names></name><name><surname>Derakhshan</surname><given-names>F</given-names></name><name><surname>Zali</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Effect of addition of vitamin C to clarithromycin-amoxicillin-omeprazol triple regimen on <italic>Helicobacter pylori</italic> eradication</article-title><source>Acta Gastroenterol Belg</source><year>2009</year><volume>72</volume><fpage>222</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">19637777</pub-id></element-citation></ref><ref id="CIT0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Effect of vitamins C and E supplementation on <italic>Helicobacter pylori</italic> eradication: a meta-analysis</article-title><source>Br J Nutr</source><year>2011</year><volume>106</volume><fpage>1632</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">21810287</pub-id></element-citation></ref><ref id="CIT0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lozniewski</surname><given-names>A</given-names></name><name><surname>Duprez</surname><given-names>A</given-names></name><name><surname>Renault</surname><given-names>C</given-names></name><name><surname>Muhale</surname><given-names>F</given-names></name><name><surname>Conroy</surname><given-names>MC</given-names></name><name><surname>Weber</surname><given-names>M</given-names></name><etal/></person-group><article-title>Gastric penetration of amoxicillin in a human <italic>Helicobacter pylori</italic>-infected xenograft model</article-title><source>Antimicrob Agents Chemother</source><year>1999</year><volume>43</volume><fpage>1909</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">10428911</pub-id></element-citation></ref><ref id="CIT0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pathak</surname><given-names>A</given-names></name><name><surname>Rai</surname><given-names>P</given-names></name><name><surname>Rajput</surname><given-names>SJ</given-names></name></person-group><article-title>Stability-Indicating HPLC Method for Simultaneous Determination of clidinium bromide and chlordiazepoxide in combined dosage forms</article-title><source>J Chromatogr Sci</source><year>2010</year><volume>48</volume><fpage>235</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">20223092</pub-id></element-citation></ref><ref id="CIT0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siavoshi</surname><given-names>F</given-names></name><name><surname>Safari</surname><given-names>F</given-names></name><name><surname>Doratotaj</surname><given-names>D</given-names></name><name><surname>Khatami</surname><given-names>GR</given-names></name><name><surname>Fallahi</surname><given-names>GH</given-names></name><name><surname>Mirnaseri</surname><given-names>MM</given-names></name></person-group><article-title>Antimicrobial resistance of <italic>Helicobacter pylori</italic> isolates from Iranian adults and children</article-title><source>Arch Iran Med</source><year>2006</year><volume>9</volume><fpage>308</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">17061600</pub-id></element-citation></ref><ref id="CIT0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohanteb</surname><given-names>J</given-names></name><name><surname>Bazargani</surname><given-names>A</given-names></name><name><surname>Saberi-Firoozi</surname><given-names>M</given-names></name><name><surname>Mobasser</surname><given-names>A</given-names></name></person-group><article-title>Antimicrobial susceptibility testing of <italic>Helicobacter pylori</italic> to selected agents by agar dilution method in Shiraz-Iran</article-title><source>Indian J Med Microbiol</source><year>2007</year><volume>25</volume><fpage>374</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">18087088</pub-id></element-citation></ref><ref id="CIT0024"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooton</surname><given-names>C</given-names></name><name><surname>Dempsey</surname><given-names>C</given-names></name><name><surname>Keohane</surname><given-names>J</given-names></name><name><surname>O'Mahony</surname><given-names>S</given-names></name><name><surname>Crosbie</surname><given-names>O</given-names></name><name><surname>Lucey</surname><given-names>B</given-names></name></person-group><article-title>
<italic>Helicobacter pylori</italic>: prevalence of antimicrobial resistance in clinical isolates</article-title><source>Br J Biomed Sci</source><year>2006</year><volume>63</volume><fpage>113</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">17058710</pub-id></element-citation></ref><ref id="CIT0025"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iovene</surname><given-names>MR</given-names></name><name><surname>Romano</surname><given-names>M</given-names></name><name><surname>Pilloni</surname><given-names>AP</given-names></name><name><surname>Giordano</surname><given-names>B</given-names></name><name><surname>Montella</surname><given-names>F</given-names></name><name><surname>Caliendo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prevalence of antimicrobial resistance in eighty clinical isolates of <italic>Helicobacter pylori</italic>
</article-title><source>Chemotherapy</source><year>1999</year><volume>45</volume><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">9876204</pub-id></element-citation></ref><ref id="CIT0026"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poon</surname><given-names>SK</given-names></name><name><surname>Lai</surname><given-names>CH</given-names></name><name><surname>Chang</surname><given-names>CS</given-names></name><name><surname>Lin</surname><given-names>WY</given-names></name><name><surname>Chang</surname><given-names>YC</given-names></name><name><surname>Wang</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Prevalence of antimicrobial resistance in <italic>Helicobacter pylori</italic> isolates in Taiwan in relation to consumption of antimicrobial agents</article-title><source>Int J Antimicrob Agents</source><year>2009</year><volume>34</volume><fpage>162</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">19324524</pub-id></element-citation></ref><ref id="CIT0027"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toro</surname><given-names>C</given-names></name><name><surname>Garcia-Samaniego</surname><given-names>J</given-names></name><name><surname>Carbo</surname><given-names>J</given-names></name><name><surname>Iniguez</surname><given-names>A</given-names></name><name><surname>Alarcon</surname><given-names>T</given-names></name><name><surname>Lopez-Brea</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prevalence of primary <italic>Helicobacter pylori</italic> resistance to eight antimicrobial agents in a hospital in Madrid</article-title><source>Rev Esp Quimioter</source><year>2001</year><volume>14</volume><fpage>172</fpage><lpage>76</lpage><comment>[In Spanish]</comment><pub-id pub-id-type="pmid">11704771</pub-id></element-citation></ref><ref id="CIT0028"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolle</surname><given-names>K</given-names></name><name><surname>Nilius</surname><given-names>M</given-names></name><name><surname>Leodolter</surname><given-names>A</given-names></name><name><surname>Muller</surname><given-names>WA</given-names></name><name><surname>Malfertheiner</surname><given-names>P</given-names></name><name><surname>Konig</surname><given-names>W</given-names></name></person-group><article-title>Prevalence of <italic>Helicobacter pylori</italic> resistance to several antimicrobial agents in a region of Germany</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>1998</year><volume>17</volume><fpage>519</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">9764558</pub-id></element-citation></ref><ref id="CIT0029"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chuang</surname><given-names>CH</given-names></name><name><surname>Sheu</surname><given-names>BS</given-names></name><name><surname>Huang</surname><given-names>AH</given-names></name><name><surname>Yang</surname><given-names>HB</given-names></name><name><surname>Wu</surname><given-names>JJ</given-names></name></person-group><article-title>Vitamin C and E supplements to lansoprazole-amoxicillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-susceptible <italic>Helicobacter pylori</italic> infection</article-title><source>Helicobacter</source><year>2002</year><volume>7</volume><fpage>310</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">12390211</pub-id></element-citation></ref></ref-list></back></article>